"Antigens, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
| Descriptor ID |
D000951
|
| MeSH Number(s) |
D23.050.285
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Antigens, Neoplasm".
This graph shows the total number of publications written about "Antigens, Neoplasm" by people in this website by year, and whether "Antigens, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 4 | 2 | 6 |
| 1994 | 1 | 0 | 1 |
| 1995 | 5 | 3 | 8 |
| 1996 | 4 | 1 | 5 |
| 1997 | 4 | 1 | 5 |
| 1998 | 3 | 3 | 6 |
| 1999 | 2 | 2 | 4 |
| 2000 | 1 | 6 | 7 |
| 2001 | 3 | 4 | 7 |
| 2002 | 2 | 3 | 5 |
| 2003 | 1 | 5 | 6 |
| 2004 | 4 | 5 | 9 |
| 2005 | 7 | 2 | 9 |
| 2006 | 5 | 8 | 13 |
| 2007 | 1 | 6 | 7 |
| 2008 | 5 | 6 | 11 |
| 2009 | 8 | 4 | 12 |
| 2010 | 3 | 2 | 5 |
| 2011 | 3 | 0 | 3 |
| 2012 | 11 | 1 | 12 |
| 2013 | 4 | 9 | 13 |
| 2014 | 7 | 5 | 12 |
| 2015 | 0 | 8 | 8 |
| 2016 | 4 | 2 | 6 |
| 2017 | 4 | 3 | 7 |
| 2018 | 5 | 2 | 7 |
| 2019 | 5 | 2 | 7 |
| 2020 | 4 | 4 | 8 |
| 2021 | 4 | 3 | 7 |
| 2022 | 1 | 3 | 4 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, Neoplasm" by people in Profiles.
-
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy. Nature. 2023 Mar; 615(7953):697-704.
-
Senescent cancer cell vaccines induce cytotoxic T cell responses targeting primary tumors and disseminated tumor cells. J Immunother Cancer. 2023 02; 11(2).
-
Non-viral precision T?cell receptor replacement for personalized cell therapy. Nature. 2023 Mar; 615(7953):687-696.
-
Tcf-1 protects anti-tumor TCR-engineered CD8+ T-cells from GzmB mediated self-destruction. Cancer Immunol Immunother. 2022 Dec; 71(12):2881-2898.
-
Targeting a proteolytic neoepitope on CUB domain containing protein 1 (CDCP1) for RAS-driven cancers. J Clin Invest. 2022 02 15; 132(4).
-
Phase II Adjuvant Cancer-specific Vaccine Therapy for Esophageal Cancer Patients Curatively Resected After Preoperative Therapy With Pathologically Positive Nodes; Possible Significance of Tumor Immune Microenvironment in its Clinical Effects. Ann Surg. 2022 01 01; 275(1):e155-e162.
-
Criteria to make animal studies more relevant to treating human cancer. Curr Opin Immunol. 2022 02; 74:25-31.
-
Effector T?cell responses unleashed by regulatory T?cell ablation exacerbate oral squamous cell carcinoma. Cell Rep Med. 2021 09 21; 2(9):100399.
-
Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma. Immunol Invest. 2022 Jul; 51(5):1498-1514.
-
Efficacy of Intranodal Neoantigen Peptide-pulsed Dendritic Cell Vaccine Monotherapy in Patients With Advanced Solid Tumors: A Retrospective Analysis. Anticancer Res. 2021 Aug; 41(8):4101-4115.